<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifty three patients (pts) received an allogeneic hematopoietic transplant using peripheral blood progenitor cells (PBPC) </plain></SENT>
<SENT sid="1" pm="."><plain>Diagnosis were <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in 16 pts, <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) in 15, <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in first <z:hpo ids='HP_0011010'>chronic</z:hpo> phase in 12, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in 4, <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> in 3 and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, major thalasemia and <z:e sem="disease" ids="C0026705" disease_type="Disease or Syndrome" abbrv="">Hunter's syndrome</z:e> in one each </plain></SENT>
<SENT sid="2" pm="."><plain>Mean age was 20 years-old (2-55), 28 males and 25 females </plain></SENT>
<SENT sid="3" pm="."><plain>Conditioning regimens were total body irradiation with 1200 cGy and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 120 mg/kg in 38 pts, <z:chebi fb="0" ids="28901">busulfan</z:chebi> 16 mg/kg and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 120 mg/kg in 10 pts, total lymphoid irradiation and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> in 3, 2 pts received other chemotherapy based conditionings </plain></SENT>
<SENT sid="4" pm="."><plain>PBPC were infused unmanipulated through a central catheter </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft versus host disease</z:e> (GVHD) prophylaxis was cyclosporin and short course <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Donors were 6/6 HLA compatible siblings in 52 cases and 5/6 match in one case </plain></SENT>
<SENT sid="7" pm="."><plain>PBPC mobilization was done with G-CSF at a dose of 10 micrograms/kg/day subcutaneously for four days, pheresis started on day 5 </plain></SENT>
<SENT sid="8" pm="."><plain>Bone marrow harvest was also done in the first thirty cases </plain></SENT>
<SENT sid="9" pm="."><plain>Mean cellularities for CD34, CD3, CD4, CD8, CD56, CD19 (cel x 10(6)/kg) were 4.12; 4.59; 2.57; 1.9; 0.55 and 0.68, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>Mean recovery of neutrophils &gt; 500/microL was obtained on day +11 and platelets &gt; 20,000/microL on day +13 </plain></SENT>
<SENT sid="11" pm="."><plain>Patients were hospitalized for a mean period of 26 days (range 18-39) and days with parenteral antibiotics were 12.2 (5-45) </plain></SENT>
<SENT sid="12" pm="."><plain>Two pts had <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">venoocclusive disease of the liver</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Transplant related mortality was 15% </plain></SENT>
<SENT sid="14" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> (GVHD) was observed in 43.4% of pts, only 5 pts had <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD III or IV </plain></SENT>
<SENT sid="15" pm="."><plain>Mean time for aGVHD diagnosis was +23 (8-76) </plain></SENT>
<SENT sid="16" pm="."><plain>Forty three pts were evaluable for <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD with a mean follow-up of 18 months (4-39) </plain></SENT>
<SENT sid="17" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> GVHD was observed in 26.4% by day +240, only 2 pts developed severe cGVHD </plain></SENT>
<SENT sid="18" pm="."><plain>The present experience demonstrates an acceptable incidence for cGVHD; however, taking into account recent reports showing an increase of this complication, it seems reasonable not to perform this procedure for non-malignant diseases in which graft versus <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> effect is not to be expected </plain></SENT>
</text></document>